Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: Implications for inflammation associated bone loss

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 1185-1190

  Kaur, K ^a   Hardy, R ^a   Ahasan, M M ^a   Eijken, M ^b   Van Leeuwen, J P ^b   Filer, A ^a   Thomas, A M ^c   Raza, K ^a   Buckley, C D ^a   Stewart, P M ^a   Rabbitt, E H ^a   Hewison, M ^d   Cooper, M S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^d JOINT REPLACEMENT INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE; CANCER CELL; CELL TYPE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; OSTEOBLAST; OSTEOLYSIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; OSTEOBLASTS; OSTEOSARCOMA; SYNOVIAL MEMBRANE; TUMOR CELLS, CULTURED;

EID: 77953704495     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.107466     Document Type: Article

References (29)

1. Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-51.
2. Schett G. Review: Immune cells and mediators of inflammatory arthritis. Autoimmunity 2008;41:224-9.
3. Roldán JF, Del Rincón I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J Rheumatol 2006;33:508-16.
4. Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 2006;8:R108.
5. Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 2001;16:1037-44.
6. Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204-10.
7. Cooper MS, Walker EA, Bland R, et al. Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone 2000;27:375-81.
8. Cooper MS, Rabbitt EH, Goddard PE, et al. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 2002;17:979-86.
9. Cooper MS, Blumsohn A, Goddard PE, et al. 11Beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab 2003;88:3874-7.
10. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
11. Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998;83:1325-35.
12. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349:1210-13.
13. Tomlinson JW, Moore J, Cooper MS, et al. Regulation of expression of 11betahydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 2001;142:1982-9.
14. Eijken M, Hewison M, Cooper MS, et al. 11Beta-hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 2005;19:621-31.
15. Eijken M, Koedam M, van Driel M, et al. The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 2006;248:87-93.
16. Hermoso MA, Matsuguchi T, Smoak K, et al. Glucocorticoids and tumor necrosis factor alpha cooperatively regulate toll-like receptor 2 gene expression. Mol Cell Biol 2004;24:4743-56.
17. Trujillo ME, Lee MJ, Sullivan S, et al. Tumor necrosis factor alpha and glucocorticoid synergistically increase leptin production in human adipose tissue: role for p38 mitogen-activated protein kinase. J Clin Endocrinol Metab 2006;91:1484-90.
18. Homma T, Kato A, Hashimoto N, et al. Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. Am J Respir Cell Mol Biol 2004;31:463-9.
19. Li W, Gao L, Wang Y, et al. Enhancement of cortisol-induced 11beta-hydroxysteroid dehydrogenase type 1 expression by interleukin 1beta in cultured human chorionic trophoblast cells. Endocrinology 2006;147:2490-5.
20. Schmidt M, Weidler C, Naumann H, et al. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum 2005;52:1711-20.
21. Haas CS, Creighton CJ, Pi X, et al. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 2006;54:2047-60.
22. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
23. Escher G, Galli I, Vishwanath BS, et al. Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J Exp Med 1997;186:189-98.
24. Zhang TY, Ding X, Daynes RA. The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J Immunol 2005;174:879-89. (Pubitemid 40094283)
25. Rauz S, Walker EA, Shackleton CH, et al. Expression and putative role of 11 betahydroxysteroid dehydrogenase isozymes within the human eye. Invest Ophthalmol Vis Sci 2001;42:2037-42.
26. Cooper MS, Stewart PM. Glucocorticoids and bone mineral content in the childhood nephrotic syndrome. N Engl J Med 2004;351:2655-7; author reply 2655-7.
27. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.
28. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, et al. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 2003;21:155-60.
29. Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008;17:481-96.